IAP antagonists: promising candidates for cancer therapy

Drug Discovery Today

Volumn 15, Issue 5-6, 2010, Pages 210-219

  Mannhold, Raimund ^a   Fulda, Simone ^b   Carosati, Emanuele ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AEG 40730; ALANYLVALYLPROLYLISOLEUCINE; AMINOTHIAZOLE DERIVATIVE; ANTINEOPLASTIC AGENT; ARYLSULFONAMIDE DERIVATIVE; BORTEZOMIB; BV 6; EMBELIN; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; INHIBITOR OF APOPTOSIS PROTEIN ANTAGONIST; LBW 242; POLYPHENYLUREA DERIVATIVE; SALINOSPORAMIDE A; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SM 130; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TWX 006; TWX 024; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; BINDING AFFINITY; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; COLON CARCINOMA; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IC 50; MULTIPLE MYELOMA; NONHUMAN; PROSTATE CARCINOMA; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS; PROTEIN TRANSPORT;

EID: 77649239222     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.01.003     Document Type: Review

References (60)

1. Kerr J.F., et al. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26 (1972) 239-257
2. Lockshin R.A., and Williams C.M. Programmed cell death. II. Endocrine potentiation of the breakdown of the intersegmental muscles of silkmoths. J. Insect Physiol. 10 (1964) 643-649
3. Lockshin R.A., and Zakeri Z. Cell death in health and disease. J. Cell. Mol. Med. 11 (2007) 1214-1224
4. Lowe S.W., et al. Intrinsic tumour suppression. Nature 432 (2004) 307-315
5. LaCasse E.C., et al. IAP-targeted therapies for cancer. Oncogene 27 (2008) 6252-6275
6. Hunter A.M., et al. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12 (2007) 1543-1568
7. Vucic D., and Fairbrother W.J. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin. Cancer Res. 13 (2007) 5995-6000
8. Sun H., et al. Design of small-molecule peptidic and nonpeptidic Smac mimetics. Acc. Chem. Res. 41 (2008) 1264-1277
9. Crook N.E., et al. An apoptosis-inhibiting baculovirus gene with a zinc-finger-like motif. J. Virol. 67 (1993) 2168-2174
10. Mace P.D., et al. Assembling the building blocks: structure and function of inhibitor of apoptosis proteins. Cell Death Differ. 17 (2010) 46-53
11. Liu Z., et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 408 (2000) 1004-1008
12. Wu G., et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 408 (2000) 1008-1012
13. Srinivasula S.M., and Ashwell J.D. IAPs: what's in a name?. Mol. Cell 30 (2008) 123-135
14. Scott F.L., et al. XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. EMBO J. 24 (2005) 645-655
15. Riedl S.J., and Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol. 5 (2004) 897-907
16. Schile A.J., et al. Regulation of apoptosis by XIAP ubiquitin-ligase activity. Genes Dev. 22 (2008) 2256-2266
17. Lu M., et al. XIAP induces NF-κB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol. Cell 26 (2007) 689-702
18. Lewis J., et al. Uncoupling of the signaling and caspase-inhibitory properties of X-linked inhibitor of apoptosis. J. Biol. Chem. 279 (2004) 9023-9029
19. Du C., et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102 (2000) 33-42
20. Verhagen A.M., et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing inhibitor of apoptosis (IAP) proteins. Cell 102 (2000) 43-53
21. Chai J., et al. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406 (2000) 855-862
22. Srinivasula S.M., et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410 (2001) 112-116
23. Huang Y., et al. Requirement of both the second and third BIR domains for the relief of X-linked inhibitor of apoptosis protein (XIAP)-mediated caspase inhibition by Smac. J. Biol. Chem. 278 (2003) 49517-49522
24. Creagh E.M., et al. Smac/DIABLO antagonizes ubiquitin ligase activity of inhibitor of apoptosis proteins. J. Biol. Chem. 279 (2004) 26906-26914
25. Yang Q.-H., and Du Ch. Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLa cells. J. Biol. Chem. 279 (2004) 16963-16970
26. Oost T.K., et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J. Med. Chem. 47 (2004) 4417-4426
27. Sun H., et al. Structure-based design of potent, conformationally constrained Smac mimetics. J. Am. Chem. Soc. 126 (2004) 16686-16687
28. Sun H., et al. Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J. Med. Chem. 47 (2004) 4147-4150
29. Sun H., et al. Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. J. Med. Chem. 49 (2006) 7916-7920
30. Sun H., et al. Structure-based design, synthesis, evaluation and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). J. Med. Chem. 51 (2008) 7169-7180
31. Zhang B., et al. Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of caspases. J. Med. Chem. 51 (2008) 7352-7355
32. Zobel K., et al. Design, Synthesis, and Biological Activity of a Potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem. Biol. 1 (2006) 525-534
33. Palermo M.G., et al. Preparation of peptides as inhibitors of IAP. PCT Int. Appl. (2005) WO 2005097791
34. Kapa P.K., et al. Process for preparing N-[1-cyclohexyl-2-oxo-2-(6-phenethyl-octahydro-pyrrolo[2,3-c]pyridin-1-yl)-ethyl]-2-methylamino-propionamide and related compounds. PCT Int. Appl. (2006) WO 2006107963
35. Chauhan D., et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma. Blood 109 (2007) 1220-1227
36. Gaither A., et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res. 67 (2007) 11493-11498
37. Mastrangelo E., et al. Targeting the X-linked inhibitor of apoptosis protein (XIAP) through 4-substituted azabicyclo[5.3.0]alkane Smac-mimetics, Structure, activity and recognition principles. J. Mol. Biol. 384 (2008) 673-689
38. Cossu F., et al. Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2. Biochem. Biophys. Res. Commun. 378 (2009) 162-167
39. Huang J.-W., et al. Fragment-based design of small molecule X-linked inhibitor of apoptosis protein inhibitors. J. Med. Chem. 51 (2008) 7111-7118
40. Bockbrader K.M., et al. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 24 (2005) 7381-7388
41. Park C.-M., et al. Non-peptidic small molecule inhibitors of XIAP. Bioorg. Med. Chem. Lett. 15 (2005) 771-775
42. Nikolovska-Coleska Z., et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine threedimensional structure database. J. Med. Chem. 47 (2004) 2430-2440
43. Chen J., et al. Design, synthesis and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. Bioorg. Med. Chem. Lett. 16 (2006) 5805-5808
44. Wu T.Y.H., et al. Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/Caspase-3 interaction. Chem. Biol. 10 (2003) 759-767
45. Schimmer A.D., et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5 (2004) 25-35
46. Berezovskaya O., et al. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res. 65 (2005) 2378-2386
47. Li L., et al. A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death. Science 305 (2004) 1471-1474
48. Nikolovska-Coleska Z., et al. Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains. Anal. Biochem. 374 (2008) 87-98
49. Sun H., et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J. Am. Chem. Soc. 129 (2007) 15279-15294
50. Nikolovska-Coleska Z., et al. Interaction of a cyclic, bivalent Smac mimetic with the X-linked inhibitor of apoptosis protein. Biochemistry 47 (2008) 9811-9824
51. Gao Z., et al. A dimeric Smac/Diablo peptide directly relieves caspase-3 inhibition by XIAP, Dynamic and cooperative regulation of XIAP by Smac/Diablo. J. Biol. Chem. 282 (2007) 30718-30727
52. Varfolomeev E., et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131 (2007) 669-681
53. Splan K.E., et al. Biochemical basis for enhanced binding of peptide dimers to X-Linked inhibitor of apoptosis protein. Biochemistry 46 (2007) 11938-11944
54. Vince J.E., et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131 (2007) 682-693
55. Zender L., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125 (2006) 1253-1267
56. Bertrand M.J., et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30 (2008) 689-700
57. Lu J., et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 68 (2008) 9384-9393
58. Ndubaku C., et al. Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem. Biol. 4 (2009) 557-566
59. Wist A.D., et al. Structure-activity based study of the Smac-binding pocket within the BIR3 domain of XIAP. Bioorg. Med. Chem. 15 (2007) 2935-2943
60. Goodford P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28 (1985) 849-857